Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Leases: 2015-2018

Historic Capital Leases for Seres Therapeutics (MCRB) over the last 4 years, with Dec 2018 value amounting to $6.8 million.

  • Seres Therapeutics' Capital Leases fell 24.62% to $6.8 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.8 million, marking a year-over-year decrease of 24.62%. This contributed to the annual value of $6.8 million for FY2018, which is 24.62% down from last year.
  • According to the latest figures from FY2018, Seres Therapeutics' Capital Leases is $6.8 million, which was down 24.62% from $9.0 million recorded in FY2017.
  • In the past 5 years, Seres Therapeutics' Capital Leases registered a high of $10.7 million during FY2016, and its lowest value of $586,000 during FY2015.
  • Moreover, its 3-year median value for Capital Leases was $9.0 million (2017), whereas its average is $8.8 million.
  • In the last 5 years, Seres Therapeutics' Capital Leases spiked by 1,731.06% in 2016 and then fell by 24.62% in 2018.
  • Seres Therapeutics' Capital Leases (Yearly) stood at $586,000 in 2015, then surged by 1,731.06% to $10.7 million in 2016, then declined by 16.23% to $9.0 million in 2017, then decreased by 24.62% to $6.8 million in 2018.